"Robust disease burden data are essential for introducing a new vaccine. PneumoADIP is gaining the advantage by gathering this evidence to aid the decision to introduce pneumococcal vaccines."
National Public Health Institute,
Pneumococcal disease is on the map in 56 countries with PneumoADIP support
Decision makers in developing countries need accurate data at a local and regional level in order to justify dedicating resources to combating this disease. Supporting research and surveillance in these countries to provide such data is one of PneumoADIP’s strategic goals.
In the past three years, the value of pneumococcal surveillance networks has been more evident than ever. With technical and financial support from PneumoADIP and WHO, the pneumococcal surveillance networks are collecting standardized pneumococcal disease data and communicating their local data to regional network partners, including surveillance sites, ministries of health, multilateral organizations, and donors supporting vaccination.
Please select a site to view PneumoADIP activities.
PneumoADIP has greatly expanded its Small Grants Program, which enables broader geographic involvement and a greater variety of projects than is possible by other means.
Small grants can represent a great investment in developing countries, achieving a lot in a short time and sowing the seeds for larger projects. In many cases, data from different projects may be complementary, acting as pieces of a puzzle that build up to create a bigger picture.
Based on the recommendations from PneumoADIP's Scientific Advisors, PneumoADIP created the Asian Field Site Initiative to select and develop sites for vaccine impact studies throughout Asia. After a rigorous evaluation process, 8 field sites in Asia were selected for further development. The goal of the initiative is to identify sites that represent the diversity of Asia where the vaccine's impact against key outcomes of regional interest can be evaluated in a way that accelerates evidence-based decision-making in the region.
Vaccinating children in developing countries against pneumococcal infection has great potential to save lives and reduce disability, but will also require substantial new financing. In order to assist decisions about investment in pneumococcal vaccine purchase and to help inform PneumoADIP priorities, Dr. Tracy Lieu and her colleagues are undertaking a cost-effectiveness analysis of pneumococcal vaccination in GAVI-eligible developing countries. Preliminary analyses indicate that pneumococcal vaccinations in GAVI-eligible countries are highly cost effective in saving lives and averting treatment costs and long-term costs due to disability. The aim of this project is to provide robust estimations of lives saved and costs averted per cost of vaccination – these types of comparable units of cost and benefits would facilitate decision makers to prioritize interventions.
PneumoADIP is supporting WHO to develop official estimates of global pneumococcal disease burden, including deaths in children. These figures will assist countries when prioritizing among the many health needs of children and help with efforts to increase financing by illustrating the potential health benefits of vaccination.
This multi-site study aims to evaluate the utility of Binax Now® (an antigen test for Streptococcus pneumoniae) as an adjunct to culture for the diagnosis of pneumococcal meningitis in a variety of settings. Particularly in rural areas, a rapid test tool like Binax Now® may improve the diagnosis and treatment of children with meningitis and with documenting local pneumococcal meningitis. This study is being built on the existing pneumococcal surveillance networks.
In China, local researchers will conduct a study designed to evaluate the usefulness of the orotracheal aspiration (OTA) method, a clinical technique for diagnosing pneumococcal pneumonia, among children under 3 years of age. Testing the specificity and sensitivity of alternative diagnosing techniques such as OTA provides researchers and clinicians better ways to diagnose, document and treat pneumococcal disease.
PneumoADIP and WHO support ancillary studies from pneumococcal vaccine clinical trials in South Africa, The Gambia and the Philippines. Funding for these ancillary studies allows researchers to conduct various in-depth analyses on their existing vaccine trial data. The majority of the ancillary studies evaluate the usefulness of various diagnostic techniques in confirming pneumococcal disease cases at diverse geographic settings in order to better estimate the potential health and economic impact of pneumococcal vaccination.